Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace
05 déc. 2024 08h30 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is...
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease
11 juil. 2024 08h00 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, July 11, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (formerly known as AAV2-GDNF) is being studied for the treatment of...
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
09 juil. 2024 20h00 HE
|
Io Therapeutics, Inc.
Io Therapeutics presented data on the potential of IRX4204 for treatment of aging-related neurodegeneration, Parkinson's disease, and Alzheimer's disease
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
16 avr. 2024 08h03 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the...
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
08 mars 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases at AD/PD™ 2024
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
05 mars 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that...
ONWARD verstärkt Führungsteam auf Schlüsselpositionen in den Bereichen Clinical & Regulatory sowie Marketing
06 nov. 2023 12h13 HE
|
ONWARD Medical NV
EINDHOVEN, Niederlande, LAUSANNE, Schweiz und BOSTON, MA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Das Medizintechnikunternehmen ONWARD Medical N.V. (Euronext: ONWD), das innovative Therapien zur...
ONWARD renforce son management avec des nominations clés dans le domaine clinique et réglementaire et en marketing
06 nov. 2023 12h13 HE
|
ONWARD Medical NV
EINDHOVEN, Pays-Bas, LAUSANNE, Suisse, et BOSTON, MA, Etats-Unis, 06 nov. 2023 (GLOBE NEWSWIRE) -- ONWARD Medical SA (Euronext: ONWD), société de technologie médicale créant des thérapies innovantes...
ONWARD versterkt management met kernfuncties in Klinische & Regelgevende en Marketingafdelingen
06 nov. 2023 12h13 HE
|
ONWARD Medical NV
EINDHOVEN, Nederland, LAUSANNE, Zwitserland & BOSTON, MA, VS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), het medische technologiebedrijf dat innovatieve therapieën...
Nature Medicine Publication Highlights Potential for ONWARD® ARC Therapy™ to Improve Mobility After Parkinson’s Disease
06 nov. 2023 12h13 HE
|
ONWARD Medical NV
EINDHOVEN, the Netherlands, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore...